GLI1 and neoplasm: GANT-61 inhibits both Gli1/2 downstream effectors and decreases tumor growth in vivo and in vitro in a variety of cancers, including prostate and ovarian cancers (Rimkus et al., 2016; Carpenter and Ray, 2019).